

Servatus strengthens board with new appointment

04 May 2022 | News

New Board appointment deepens and consolidates Servatus' extensive commercial and scientific expertise for its global biotherapeutics programs



Servatus Limited, an Australian biopharmaceutical company delivering leading novel autoimmune and microbiome therapies, has announced the appointment of Dr Uwe Buecheler to its Board as Non-Executive Director.

Dr Buecheler is a leading molecular biologist with more than 30 years of biopharmaceuticals experience at Boehringer Ingelheim in Germany.

Dr Uwe Buecheler's appointment brings significant commercial and scientific experience to the Servatus Board at a time when the company is bolstering its Australian research and development capabilities for market-leading live biotherapeutic programs, including clinical trials for IBS-C, insomnia, rheumatoid arthritis and other health problems associated with the gut-microbiome-brain axis.

Dr Buecheler serves as Senior Advisor Biopharmaceuticals to the Board of Management Directors of Boehringer Ingelheim, having joined the Company in 1991. During his time at Boehringer Ingelheim, Dr Buecheler held a variety of senior roles across CMC development, Regulatory, Biosafety, Quality, and as Site Head and Lead for an expansion of Boehringer Ingelheim's Global Operations Network in Europe, the US and China. He pioneered 1st Biologics MAH approval in Shanghai and played a key role in major expansion projects in aseptic processing, microbial manufacturing and large-scale mammalian cell culture operations. Dr Buecheler has overseen more than 30 Biologics approvals/launches, including more than five top 20 global biopharmaceuticals.